Overview

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
Phase:
Phase 1
Details
Lead Sponsor:
Norgine